» Articles » PMID: 22973371

Relationships Between Acylated Ghrelin with Growth Hormone, Insulin Resistance, Lipid Profile, and Cardio Respiratory Function in Lean and Obese Men

Overview
Journal J Res Med Sci
Specialty General Medicine
Date 2012 Sep 14
PMID 22973371
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acylated ghrelin, biologically active form of ghrelin, activates growth hormone (GH) secretagogue receptor 1a and play a role in regulating of energy balance. The purpose of this study was to survey relationships between acylated ghrelin with GH, insulin resistance, lipid profile, and cardio respiratory function in lean and obese men.

Methods: Nineteen obese men (body mass index 31.0 ± 3.5 kg/m(2), aged 27.5 ± 5.8 year) and the same number of lean men (body mass index = 18.47 ± 2.1 kg/m(2), aged 26.9 ± 5.6 year) were selected if they had no experience of regular physical activity during six month ago. After 12 hour fasting, blood samples were collected and blood parameters as well as maximal oxygen uptake (as indicator of cardiorespiratory function) was assessed.

Results: Insulin levels and HOMA-IR (homeostasis model assessment of insulin resistance) were higher, and GH, acylated ghrelin and maximal oxygen uptake levels were lower, in obese versus lean men (p < 0.01). No significant differences were observed in systolic and diastolic blood pressure, fasting blood glucose, and lipid profiles between the two groups (p > 0.01). Plasma acylated ghrelin concentrations in obese and lean men were negatively correlated to body weight (r= -0.50, r= -0.43, respectively), body fat percent (r = -0.53, r = -0.44, respectively), body mass index (r = -0.53, r = -0.49, respectively), insulin (r = -0.42, r = -0.40, respectively) and HOMA-IR (r = -0.48, r = -0.45, respectively), and positively correlated to GH levels (r = 0.37, r = 0.31, respectively) and maximal oxygen uptake (r = 0.33, r = 0.31, respectively) (p < 0.01). No significant correlations were observed between plasma acylated ghrelin concentrations and systolic and diastolic blood pressure, fasting blood glucose, and lipid profiles in both groups (p > 0.01).

Conclusions: Obese and lean inactive young men had different levels of acylated ghrelin, GH, insulin, insulin resistance index, cardiorespiratory function and body fat percent. Body fat percent, insulin, and GH levels appear to be best determinant factors of acylated ghrelin levels. Also, in both obese and lean young men, higher levels of cardiovascular function were associated with higher levels of acylated ghrelin.

Citing Articles

Differences in gastrointestinal hormones and appetite ratings between individuals with and without obesity-A systematic review and meta-analysis.

Aukan M, Coutinho S, Pedersen S, Rae Simpson M, Martins C Obes Rev. 2022; 24(2):e13531.

PMID: 36416279 PMC: 10078575. DOI: 10.1111/obr.13531.


Circulating acyl and des-acyl ghrelin levels in obese adults: a systematic review and meta-analysis.

Wang Y, Wu Q, Zhou Q, Chen Y, Lei X, Chen Y Sci Rep. 2022; 12(1):2679.

PMID: 35177705 PMC: 8854418. DOI: 10.1038/s41598-022-06636-3.


The Correlation Between Circulating Ghrelin and Insulin Resistance in Obesity: A Meta-Analysis.

Zhang C, Wang L, Wang R, Liu Y, Song L, Yuan J Front Physiol. 2018; 9:1308.

PMID: 30298019 PMC: 6160589. DOI: 10.3389/fphys.2018.01308.


Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.

Denney W, Sonnenberg G, Carvajal-Gonzalez S, Tuthill T, Jackson V Br J Clin Pharmacol. 2016; 83(2):326-338.

PMID: 27621150 PMC: 5237700. DOI: 10.1111/bcp.13127.


Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.

Kong J, Chuddy J, Stock I, Loria P, Straub S, Vage C Br J Pharmacol. 2016; 173(9):1452-64.

PMID: 26784385 PMC: 4831304. DOI: 10.1111/bph.13439.


References
1.
Tritos N, Kokkotou E . The physiology and potential clinical applications of ghrelin, a novel peptide hormone. Mayo Clin Proc. 2006; 81(5):653-60. DOI: 10.4065/81.5.653. View

2.
Cink R, Thomas T . Validity of the Astrand-Ryhming nomogram for predicting maximal oxygen intake. Br J Sports Med. 1981; 15(3):182-5. PMC: 1858756. DOI: 10.1136/bjsm.15.3.182. View

3.
Saad M, Bernaba B, Hwu C, Jinagouda S, Fahmi S, Kogosov E . Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab. 2002; 87(8):3997-4000. DOI: 10.1210/jcem.87.8.8879. View

4.
Yildiz B, Suchard M, Wong M, McCann S, Licinio J . Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A. 2004; 101(28):10434-9. PMC: 478601. DOI: 10.1073/pnas.0403465101. View

5.
Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal M, Hosoda H . Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes. 2002; 51(1):124-9. DOI: 10.2337/diabetes.51.1.124. View